Subscribe To
SGMT / Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH
SGMT News
By GlobeNewsWire
October 18, 2023
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing no more_horizontal
By Seeking Alpha
September 27, 2023
Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH
Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows pro more_horizontal